摘要
目的:探讨黄芪多糖(astragalus polysaccharide,APS)对哮喘小鼠气道重构的干预作用。方法:60只4～6周龄SPF(Specific PathogenFree)级BALB/c小鼠,随机均分为对照组、哮喘组、APS治疗组和地塞米松(dexamethasone,DXM)阳性对照组;用卵蛋白(ovalbumin,OVA)致敏/激发哮喘;APS治疗组和DXM阳性对照组分别用APS和DXM肌肉注射治疗。采用二步法免疫组化技术对小鼠肺组织α平滑肌肌动蛋白(smooth muscle actin-α,α-SMA)表达进行检测,采用计算机图像分析系统对气道重塑进行分析。结果:与对照组对比,哮喘组小鼠肺泡灌洗液(bronchoalveolar lavage fliud,BALF)中白细胞计数显著增加(P<0.01),α-SMA强阳性表达,气道壁厚度(d/Pi)、气道壁面积(WA/Pi)、气道平滑肌面积(Wam/Pi)和平滑肌细胞计数(N/Pi)均明显增加(P<0.05或P<0.01);与哮喘组对比,APS治疗组和DXM阳性对照组BALF中细胞计数显著减少(P<0.001),α-SMA阳性表达,d/Pi、WA/Pi、Wam/Pi和N/Pi均显著减小(P<0.05或P<0.01)。结论:APS可抑制哮喘小鼠的气道重塑,这种抑制作用可能是通过调节α-SMA的表达来实现的。
AIM：To evaluate the effects of astragalus polysaccharide（APS） on the airway remodeling in asthmatic mice.METHODS：Sixty SPF BALB/c mouse were randomly divided into four groups：control group,asthmatic model group,APS treatment group and dexamethasone （DXM） treatment group.The experimental groups were sensitized with ovalbumin（OVA）, cured with APS or DXM,then excited with 1% OVA.The method of two-step immunohisto-chemistry and techniques of computer-assisted image analysis were used to detect the changes of the airway remodelling and the expression ofα-SMA. RESULTS：Compared with those in the control group,in asthmatic model group,the counts of inflammation cells were significantly increased（P〈0.01）;the expression ofα-SMA was strongly positive;while the wall thickness （d/Pi） and wall area（WA/Pi） of the bronchi were significantly increased（P〈0.05 or P〈0.01）,and so did the area of smooth muscle （Wam/Pi） and the count of smooth muscle cells （N/Pi）（P〈0.05 or P〈0.01）.Compared with the asthmatic model group,in both APS inhalation group and DXM treatment group,the re- sults ofα-SMA showed positive expression,the numbers of inflammation cells were notably decreased （P〈0.01）,there also were great decreases of d/Pi,WA/Pi,Wam/Pi and N/Pi. CONCLUSION：With the treatment of APS,the course of the airway remodeling can be inhibited. The regulation on the expression level ofα-SMA may be one of the mechanisms controlling the airway remodeling.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2010年第4期385-390,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
广东省科技计划项目(2006B60101064)
